Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corporation has updated its executive severance arrangements. On May 21, 2026, the board’s Talent Committee approved a new Solventum Executive Severance Plan, effective June 1, 2026, replacing the prior plan adopted in April 2024.
The plan covers certain employees, including executive officers, if they are involuntarily terminated without misconduct or leave for good reason, subject to a release of claims. Eligible participants may receive cash severance based on continued base salary for roughly 9 to 24 months, continued incentive eligibility, a lump‑sum for medical and dental coverage, and specified equity award treatment.
For direct reports to the Chief Executive Officer, the plan generally provides 12 months of base salary plus prorated incentive compensation after an eligible termination, while current executives who previously qualified for 18 months of salary keep that level for two years. It also clarifies forfeiture and limited vesting rules for equity awards and preserves certain grandfathered rights under earlier grants.
Solventum Corporation reported the results of its annual shareholder meeting held on May 15, 2026. Shareholders elected four Class II directors—Carlos Albán, Susan D. DeVore, Shirley Edwards, and Dr. Bernard A. Harris Jr.—each receiving over 113 million votes in favor, with additional broker non-votes recorded.
Shareholders also approved, on an advisory basis, the compensation of Solventum’s named executive officers, with 105,240,522 votes for and 36,603,358 against. Finally, shareholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 156,439,674 votes for and minimal opposition.
ALBAN CARLOS reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carlos Alban received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents the right to receive 1 share of Solventum common stock upon settlement, so this award covers 3,300 underlying shares. The RSUs were granted at no cash cost and will fully vest on May 15, 2027, if he continues serving through that date. Following this grant, Alban holds 3,300 RSUs directly, reflecting a routine, compensation-related equity award rather than an open-market share purchase or sale.
COX CARRIE SMITH reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carrie Smith Cox received a grant of 4,848 Restricted Stock Units, each representing one share of common stock upon settlement. These RSUs were awarded at no cash cost and will fully vest on May 15, 2027, if her service continues through that date.
Solventum Corp director Susan D. DeVore received a grant of 3,300 Restricted Stock Units (RSUs) that convert into the same number of common shares upon settlement. The award was given at no cash cost to her and represents equity-based compensation rather than an open-market purchase.
The RSUs are scheduled to fully vest on May 15, 2027, provided she continues to serve through that date. Following this grant, her reported holdings in RSUs tied to common stock total 3,300 units, aligning her compensation more closely with future company performance.
Edwards Shirley Ann reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Shirley Ann Edwards received a grant of 3,300 Restricted Stock Units as equity compensation. Each RSU represents a right to receive one share of common stock upon settlement. The RSUs will fully vest on May 15, 2027, if she remains in service through that date.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Glenn A. Eisenberg received a grant of 3,300 Restricted Stock Units, each representing a contingent right to one share of common stock upon settlement. These RSUs vest in full on May 15, 2027, subject to continued service, leaving him with 3,300 derivative units reported after this award.
Harris Bernard A Jr reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Harris Bernard A Jr received a grant of 3,300 Restricted Stock Units, each representing a right to receive one share of common stock upon settlement. These RSUs were awarded at no cash cost to him and will fully vest on May 15, 2027, if he continues in service through that date.
MAY KAREN J reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Karen J. May received a grant of 3,300 Restricted Stock Units (RSUs). These RSUs give her the right to receive 3,300 shares of Solventum common stock upon settlement. The award fully vests on May 15, 2027, subject to her continued service with the company, and represents her full reported RSU holdings after this grant.
Mily Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Mily Elizabeth received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Solventum common stock upon settlement. The RSUs will fully vest on May 15, 2027, if she continues serving through that date.
Following this equity award, she holds 3,300 RSUs directly. This is a compensation-related grant rather than an open-market share purchase or sale.